

Emanuel Krebs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5549727/publications.pdf>

Version: 2024-02-01

40
papers

649
citations

586496

16
h-index

685536

24
g-index

40
all docs

40
docs citations

40
times ranked

882
citing authors

#	ARTICLE	IF	CITATIONS
1	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	1.6	5
2	The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2021, 72, e828-e834.	2.9	30
3	Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider Application. <i>Current HIV/AIDS Reports</i> , 2021, 18, 176-185.	1.1	11
4	The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1222-1238.	0.8	1
5	Opioid analgesic prescribing for opioid-naïve individuals prior to identification of opioid use disorder in British Columbia, Canada. <i>Addiction</i> , 2021, 116, 3422-3432.	1.7	2
6	Diagnosis of Opioid Use Disorder by Youths Assessed in Acute Care Settings in British Columbia, Canada. <i>Journal of Pediatrics</i> , 2021, 232, 243-250.	0.9	0
7	Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV. <i>Aids</i> , 2021, Publish Ahead of Print, 2169-2179.	1.0	0
8	Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012–2018. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108799.	1.6	6
9	Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. <i>Lancet HIV</i> , 2021, 8, e581-e590.	2.1	9
10	The cascade of care for opioid use disorder among youth in British Columbia, 2018. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108404.	1.5	9
11	Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	2
12	The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013–14. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108714.	1.5	1
13	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020, 34, 447-458.	1.0	36
14	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. <i>Value in Health</i> , 2020, 23, 1534-1542.	0.1	3
15	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. <i>Medical Decision Making</i> , 2020, 40, 718-721.	1.2	4
16	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e036102.	0.8	17
17	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020, 222, S301-S311.	1.9	4
18	Ending the HIV epidemic in the USA: an economic modelling study in six cities. <i>Lancet HIV</i> , 2020, 7, e491-e503.	2.1	44

#	ARTICLE	IF	CITATIONS
19	Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. <i>Medical Decision Making</i> , 2020, 40, 3-16.	1.2	25
20	“Ending the Epidemic” Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic. <i>Clinical Infectious Diseases</i> , 2020, 71, 2968-2971.	2.9	25
21	Can the “Ending the HIV Epidemic”™ initiative transition the USA towards HIV/AIDS epidemic control?. <i>Aids</i> , 2020, 34, 2325-2328.	1.0	4
22	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. , 2020, 12, 20-27.		0
23	Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. <i>Lancet HIV</i> , 2019, 6, e531-e539.	2.1	18
24	Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2019, 69, 2195-2198.	2.9	20
25	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	1.7	7
26	Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. <i>PLoS ONE</i> , 2019, 14, e0217559.	1.1	31
27	Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States. <i>Aids</i> , 2019, 33, 1491-1500.	1.0	4
28	The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011–2013. <i>Clinical Infectious Diseases</i> , 2018, 66, 765-777.	2.9	15
29	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. <i>Lancet Public Health</i> , 2018, 3, e429-e437.	4.7	33
30	Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. <i>Annals of Internal Medicine</i> , 2018, 168, 10.	2.0	43
31	The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. <i>Addiction</i> , 2017, 112, 838-851.	1.7	37
32	Estimating State Transitions for Opioid Use Disorders. <i>Medical Decision Making</i> , 2017, 37, 483-497.	1.2	12
33	Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?. <i>International Journal of Drug Policy</i> , 2017, 47, 169-176.	1.6	7
34	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study. <i>Lancet HIV</i> , 2017, 4, e303-e310.	2.1	31
35	The costs of crime associated with stimulant use in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2017, 180, 304-310.	1.6	12
36	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. <i>International Journal of Drug Policy</i> , 2017, 49, 32-40.	1.6	87

#	ARTICLE	IF	CITATIONS
37	Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder. <i>Journal of Substance Abuse Treatment</i> , 2016, 67, 30-37.	1.5	13
38	Increased drug use and the timing of social assistance receipt among people who use illicit drugs. <i>Social Science and Medicine</i> , 2016, 171, 94-102.	1.8	18
39	Dynamics in the costs of criminality among opioid dependent individuals. <i>Drug and Alcohol Dependence</i> , 2014, 144, 193-200.	1.6	21
40	The Potential Epidemiological Impact of COVID-19 on the HIV/AIDS Epidemic and the Cost-Effectiveness of Linked, Opt-Out HIV Testing: A Modeling Study in Six US Cities. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2